Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

What Does the Published Research Say About Selank?

Research Context

This synthesis reviews published sources on Selank, a tuftsin analog, with emphasis on separating established findings from exploratory signals. The packet is driven mainly by review articles and preclinical studies; it does not include primary human clinical outcome data. Reviews situate Selank within tuftsin-analog biology [pubmed:28745220], peptide-based anxiolytic mechanisms [pubmed:30255741], and a broader therapeutic-peptide landscape (orthopaedics) that is tangential to Selank’s usual discussion space [pubmed:41490200].

Direct Answer

  • The packet provides no primary human clinical outcome studies of Selank.
  • Most included evidence is review-level, mechanistic in vitro, animal, or systems/methods exploratory. These do not establish clinical efficacy or generalized safety.
  • Conclusions should remain narrow and non-extrapolative; dosing and generalized safety are not justified by this evidence set.

Human Evidence (kept separate)

  • The packet includes no primary human clinical outcome studies of Selank.

Review Literature (context, not clinical outcomes)

  • Tuftsin – Properties and Analogs: Reviews Selank within the class of tuftsin-derived peptides and their properties [pubmed:28745220].
  • Peptide-based Anxiolytics: Summarizes molecular aspects of Selank’s proposed biological activity at a review/mechanistic level [pubmed:30255741].
  • Therapeutic Peptides in Orthopaedics: Provides broader peptide context; it is tangential and not direct evidence for Selank’s clinical efficacy [pubmed:41490200].

Preclinical and Exploratory Evidence

  • In vitro (cell-line) gene-expression findings:
  • IMR-32 neuroblastoma cells: Selank affected expression of genes involved in GABAergic neurotransmission [pubmed:28293190].
  • Additional reports describe changes in expression of genes linked to GABAergic neurotransmission; these are gene-expression observations without clinical endpoints [pubmed:26924987].
  • Inflammation-related gene-expression dynamics were reported under exposure to the tuftsin analog Selank; these are exploratory transcriptional findings [pubmed:24291245].
  • In vivo (animal) findings:
  • Mice: Changes in brain monoamine content and metabolites were observed, with strain-specific differences (BALB/c vs. C57Bl/6) [pubmed:19093364].
  • Comparative anticoagulant effects among regulatory proline-containing oligopeptides (including Selank) have been explored; these are preclinical observations with uncertain translational relevance [pubmed:16634437].
  • Cytokine level alterations under “social” stress conditions have been reported; these are exploratory animal findings and do not establish clinical efficacy [pubmed:32621722].

Systems and Methods (exploratory, non-outcome)

  • Functional connectomic approaches have been applied to study Selank and Semax effects; these are exploratory, methods-focused readouts and do not provide clinical outcomes. Such systems-level measures are hypothesis-generating and are not substitutes for clinical endpoints [pubmed:32342318].

What Is Not Established

  • Broad clinical efficacy claims (including generalized anti-aging or cognitive enhancement) are unsupported by this packet.
  • Mechanistic plausibility from cell or animal models does not establish clinical utility.
  • Dosing parameters, generalized safety profiles, and off-label extrapolations are not justified by the evidence summarized here.

References

  • [pubmed:41490200] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://pubmed.ncbi.nlm.nih.gov/41490200/
  • [pubmed:32342318] Functional Connectomic Approach to Studying Selank and Semax Effects. https://pubmed.ncbi.nlm.nih.gov/32342318/
  • [pubmed:28293190] GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. https://pubmed.ncbi.nlm.nih.gov/28293190/
  • [pubmed:24291245] The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. https://pubmed.ncbi.nlm.nih.gov/24291245/
  • [pubmed:28745220] Tuftsin – Properties and Analogs. https://pubmed.ncbi.nlm.nih.gov/28745220/
  • [pubmed:26924987] Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. https://pubmed.ncbi.nlm.nih.gov/26924987/
  • [pubmed:32621722] The Influence of Selank on the Level of Cytokines Under the Conditions of “Social” Stress. https://pubmed.ncbi.nlm.nih.gov/32621722/
  • [pubmed:19093364] [Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study]. https://pubmed.ncbi.nlm.nih.gov/19093364/
  • [pubmed:30255741] Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. https://pubmed.ncbi.nlm.nih.gov/30255741/
  • [pubmed:16634437] [Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application]. https://pubmed.ncbi.nlm.nih.gov/16634437/

Research-use-only catalog access

KRL product pages are gated and require age and research-use-only acknowledgement before prices, cart, or checkout are available.

Access catalog path
Browse technical product pages